Clinical experience with the medications that block the CB1 receptor, such as rimonabant, showed that inhibiting transmission at this receptor produces serious side effects (depression and suicidality). Alternatively, animal experiments show that inhibiting the break down of brain’s own endogenous ligands that activate cannabinoid receptors – which increases CB1 receptor signaling – may be another treatment approach for CUD. These studies highlight the complexity cannabis use disorder of the endocannabinoid receptor system in the brain and its role in finely modulating emotions and cognition. A more thorough understanding of this system at a mechanistic level is needed to better understand CUD and to develop better pharmacotherapies. The antipsychotic quetiapine was tested in a human laboratory study, and while it decreased some of the withdrawal symptoms in CUD, in actually increased both craving for cannabis and relapse. A goal to immediately stop cannabis completely is unrealistic for the great majority of patients with a diagnosis of moderate to severe cannabis use disorder.
- The utility of extended-release zolpidem in targeting cannabis abstinence–induced sleep disruptions has been evaluated.51 Zolpidem attenuated the effects of cannabis abstinence on sleep architecture and normalized sleep efficiency scores but did not affect sleep latency.
- Customized interventions, whether leveraging contingent rewards for adolescents, technological platforms for young adults, or pharmacological adjuncts for older individuals, have shown promise in enhancing outcomes.
- These reductions occurred without precipitating cannabis withdrawal, even for volunteers who smoked several grams of cannabis per day.
Create a file for external citation management software
All groups improved in days of abstinence and percentage in recovery, but there were no significant between-group effects. Cost-effectiveness did vary significantly by intervention, with MET/CBT5 being most cost-effective in trial 1 and ACRA the most cost-effective in trial 2. Two major limitations of the study included not having a control group amphetamine addiction treatment and not using confirmatory urine drug screenings, relying entirely on self-report for assessment of cannabis use. Additionally, evidence suggests potential gender differences in treatment response that may inform further personalization of interventions.
Cannabis and the Current State of Treatment for Cannabis Use Disorder
Some concentrated products contain THC levels exceeding 90%, significantly amplifying the risk of developing dependency. Yale doctors have also conducted studies to measure the effects of combining psychotherapies to treat cannabis dependence. One approach, call motivational interviewing, helps to turn ambivalence about quitting into energy to quit. About 10% of people who begin smoking cannabis will become addicted, and 30% of current users meet the criteria for addiction.
Through the Peaks and Valleys: Assessing and Addressing Suicide Risk in Bipolar Disorder
- It’s important to turn to healthy coping mechanisms during these times of change, such as exercising, meditating or learning a new hobby.
- These may include choosing products with low THC, avoiding daily use, reducing inhalation (to one puff every 15 minutes), purchasing from legal dispensaries (which have to comply with state regulations for contaminant testing, labeling, and dosing), and gradual tapering.
- Participants received either two 1 h sessions of the computerized DTI program or two 1 h control sessions on sleep/nutrition.
- Symptoms of cannabis withdrawal include irritability, anxiety, restlessness, appetite changes, and disrupted sleep,40 and such symptoms may contribute to difficulty achieving or maintaining abstinence.
- One way to manage cannabis withdrawal symptoms at the beginning of recovery is to take medication.
- Changes to your brain can make it hard to stop using cannabis, even if you want to.
ACRA involved of 10 individual sessions and four sessions with the caregivers to educate them on how to support the adolescent’s abstinence. MDFT included sessions (6 with the adolescent alone, 3 with the parents alone, and 6 with the whole family) and involved therapeutic processes of setting the stage, working the themes, and sealing the changes. In comparison to other drugs of abuse, many fewer clinical trials have been conducted to test the utility of pharmacotherapies for CUD. It should be noted that no pharmacological interventions have been approved yet for treatment of CUD.
Our team at Advanced Addiction Center is dedicated to setting the bar for quality treatment https://tecktastic.com/nih-study-reveals-shared-genetic-markers/ right here in Medford, Massachusetts. We create customized treatment plans and provide ongoing support every step of the way. These recovery practices work best when integrated into your daily life gradually, allowing you to build sustainable habits that support your sobriety journey. Professional guidance helps you adapt these strategies to your specific needs and circumstances. Young adults with CUD often experience disrupted brain development patterns, particularly in areas responsible for learning, memory, and emotional processing. These changes can persist even after stopping cannabis use, highlighting the importance of early intervention and prevention strategies.
CANNABIS AND CANNABINOIDS
This collective support system is a key element in ensuring that the recovery process remains connected and sustainable over time. Aelis Farma is currently sponsoring a multi-site, placebo-controlled phase 2b study in collaboration with Columbia’s medical center. Frances R. Levin, MD, the Kennedy-Leavy Professor of Psychiatry and chief of the Division on Substance Use Disorders at Columbia, is running the two-year study, which is expected to enroll 330 participants with CUD to evaluate three dose levels of AEF0117 in treating cannabis addiction.
